Table 1.
Clinical trials of “off-the-shelf” adoptive NK cell therapies for the treatment of hematological malignancies.
| Trial Identifier | Therapeutic Agent (source) | Malignancy | Age (years) | Treatment Approach | Study Phase (status) |
|---|---|---|---|---|---|
| NCT04808115 | KDS-1001 (third-party) |
CML | All | In combination with TKI therapy | Phase I (not recruiting) |
| NCT04848064 | IL-21 expanded “off-the-shelf” NK cells (third-party) |
R/R cutaneous T cell lymphoma or T cell leukaemia/lymphoma | 18+ | In combination with Mogamulizumab | Phase I (not recruiting) |
| NCT04632316 | oNKord® (third-party) |
AML | 18+ | In combination with chemotherapy | Phase I/II (recruiting) |
| NCT04220684 | mbIL-21 expanded “off-the-shelf” NK cells (third-party) |
R/R AML or MDS | 1-80 | In combination with chemotherapy | Phase I (recruiting) |
| NCT04623944 | NKX101 (related donor or third-party) |
R/R AML or MDS | 18+ | In combination with chemotherapy | Phase I (recruiting) |
| NCT04310592 | CYNK-001 (third-party iPSC) |
AML | 18-80 | In combination with chemotherapy | Phase I (recruiting) |
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; iPSC, induced pluripotent stem cell; NK, natural killer; mbIL-21, membrane-bound interleukin-21; MDS, myelodysplastic syndrome; R/R, relapsed and/or refractory; TKI, tyrosine kinase inhibitors.